MD Anderson Cancer Center
Newer drugs improve upon Gleevec for CML – CNL
MD Anderson researchers play crucial role in two New England Journal of Medicine studies showing newer drugs for chronic myeloid leukemia work faster and better than imatinib (Gleevec®).
This video requires an updated Flash player. Please update your Flash player or watch on a device which supports Flash. Flash Player Help . For additional videos, please visit our online search for videos and podcasts.
Title: Newer drugs improve upon Gleevec for CML – CNL
Summary: MD Anderson researchers play crucial role in two New England Journal of Medicine studies showing newer drugs for chronic myeloid leukemia work faster and better than imatinib (Gleevec®).
Keywords: chronic myeloid leukemia, leukemia, Gleevec, Glivec, imatinib, dasatinib, Sprycel, nilotinib, Tasigna, Kantarjian, remission, cytogenetic, toxicity, Jorge Cortes, MD Anderson, CML, MD Anderson, Cancer, M.D. Anderson, M. D. Anderson
Transcript: